Labiotech.eu

Interview 11 Dec 2017

Edwin Moses on how Ablynx has made it to the top of European biotech

Ablynx CEO Edwin Moses discusses the technology and strategy that has led its company to join the ranks of the biggest European biotechs. Ablynx, based in Belgium, has just recently joined the European billion-euro biotech club with a market cap of €1.45Bn. With positive Phase III results for its lead compound and a $230M (€195M) […]

December 11, 2017 - 8 minutesmins - By Clara Rodríguez Fernández

wilsons disease treatment wilson therapeutics sweden 1

News and Trends 8 Dec 2017

Wilson’s Disease Treatment Gets a €24.4M Equity Boost in Sweden

Wilson Therapeutics has issued new shares on Nasdaq Stockholm, raising a total of SEK 244M (€24.4M) to help bring its Wilson’s disease treatment to the market. Stockholm-based biotech Wilson Therapeutics has closed a share issue that seems to have generated quite a high demand. The company’s main shareholders, Abingworth and MVM, had to sell SEK 156.75M […]

December 8, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 8 Dec 2017

A London Biotech Aims to Overtake the Dry Eye Syndrome Market

TopiVert has released the results of a clinical trial that the company believes yielded “the best proof of concept data in dry eye syndrome.” Based in London, the biotech company TopiVert is trying to enter the $3Bn market of dry eye syndrome with a drug with the potential to work better than the options currently […]

December 8, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 8 Dec 2017

French Biotech Misfires in Phase IIb Trial for Acute Myeloid Leukemia

Erytech’s candidate, Graspa, has been unable to significantly improve overall survival in patients with acute myeloid leukemia during a Phase IIb trial. Erytech, based in Lyon, France, has developed an interesting approach to delivering drugs for the treatment of cancer and orphan diseases. The company’s eryaspase technology, Graspa, encapsulates L-asparaginase, in red blood cells. Graspa was used in combination with chemotherapy […]

December 8, 2017 - 3 minutesmins - By Alex Dale

News and Trends 7 Dec 2017

Scottish Biotech and Bluebird Bio to Develop Next Generation CAR-T Cells

TC Biopharm has scored a deal with bluebird bio for the development of the next generation of CAR-T cells, a technology giving new hope to cancer patients. With the first two CAR-T therapies now in the market, the way we treat cancer is changing. This technology has shown to be effective in a high percentage of patients […]

December 7, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 7 Dec 2017

Taking Aim at Lung Cancer: New Triple Combination Therapy Boosts Survival

A new first-line combination therapy for advanced non-squamous non-small-cell lung cancer improved progression-free survival during a Phase III trial. Scientists based at the Lung Clinic Grosshansdorf, Hamburg, and Centre Hospitalier Universitaire Vaudois, Lausanne, have presented the results of a Phase III study at the ESMO Immuno Oncology Congress 2017. The study was the first to investigate a combination […]

December 7, 2017 - 3 minutesmins - By Alex Dale

News and Trends 7 Dec 2017

French Biotech’s Type 1 Diabetes Candidate Ready to Battle it Out with Big Pharma

Adocia’s rapid-action insulin outperforms Novo Nordisk’s market approved treatment for type 1 diabetes during a Phase I study. Adocia specializes in new formulations of therapeutic proteins, particularly for the treatment of diabetes. Just last week, Adocia’s glucagon treatment for hypoglycemia was proved to be safe in a Phase I study. Today, the biotech has announced that its […]

December 7, 2017 - 3 minutesmins - By Alex Dale

News and Trends 6 Dec 2017

CRISPR Does it Again! Gene Editing Tool Identifies a New Leukemia Target

Researchers from the Wellcome Trust Sanger Institute have reported that a new target for the treatment of leukemia has been found. A new drug target for acute myeloid leukemia (AML) has been identified that could open new avenues for the development of new treatments against the deadly disease. Researchers from the Wellcome Trust Sanger Institute have […]

December 6, 2017 - 3 minutesmins - By Alex Dale

advicenne ipo rare disease children drta

News and Trends 6 Dec 2017

Update: French Biotech Closes €27M IPO to be the First to Treat Rare Disease in Children

Update (6/12/2017): Advicenne has raised a total of €27M on Euronext Paris, putting its market cap at €112M. Originally published on 21/11/2017 Advicenne is launching an IPO on Euronext Paris to raise the funds to bring the first treatment for dRTA, a rare disease of the kidneys, to the market. Advicenne, based in Nîmes, France, has officially […]

December 6, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

More News! 5 Dec 2017

PayPal Co-Founder Backs Israeli Biotech Attacking NASH with an Antibody

ChemomAb kicked off its antibody efforts as a company in 2011, and its $10M Series B has attracted none other than Peter Thiel. Israeli biotech has been attracting quite sizeable funds recently, largely those of UK investment outfit Arix Bioscience. Yesterday it was announced that Peter Theil, co-founder of PayPal and assassin of Gawker, led […]

December 5, 2017 - 2 minutesmins - By Evelyn Warner

News and Trends 5 Dec 2017

The Philippines Blocks Sanofi’s Dengue Vaccine for Safety Reasons

Following alarming research about the safety of Sanofi’s dengue vaccine, Dengvaxia, The Philippines has halted its sale, distribution and marketing “to protect the general public.” Before Sanofi Pasteur distributed its dengue vaccine, Dengvaxia, there were some concerns that it would make people sicker. Last year, researchers from top American and British institutions confirmed these suspicions […]

December 5, 2017 - 3 minutesmins - By Evelyn Warner

GeneSight eye gene therapy sight restoration

News and Trends 5 Dec 2017

Update: French Gene Therapy Yields Longer Term Sight Restoration, Eyes Phase III

Update (05/12/2017): GenSight has reported a sustained effect of its treatment GS010, which has now been shown to restore sight in patients for at least 2.5 years after administration. Phase III results for the candidate are expected next year. Originally published 14/06/2017 GenSight has announced Phase I/II data revealing that its gene therapy technology can […]

December 5, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Edwin Moses on how Ablynx has made it to the top of European biotech

Wilson’s Disease Treatment Gets a €24.4M Equity Boost in Sweden

A London Biotech Aims to Overtake the Dry Eye Syndrome Market

French Biotech Misfires in Phase IIb Trial for Acute Myeloid Leukemia

Scottish Biotech and Bluebird Bio to Develop Next Generation CAR-T Cells

Taking Aim at Lung Cancer: New Triple Combination Therapy Boosts Survival

French Biotech’s Type 1 Diabetes Candidate Ready to Battle it Out with Big Pharma

CRISPR Does it Again! Gene Editing Tool Identifies a New Leukemia Target

Update: French Biotech Closes €27M IPO to be the First to Treat Rare Disease in Children

PayPal Co-Founder Backs Israeli Biotech Attacking NASH with an Antibody

The Philippines Blocks Sanofi’s Dengue Vaccine for Safety Reasons

Update: French Gene Therapy Yields Longer Term Sight Restoration, Eyes Phase III

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!